Natera Inc (NASDAQ:NTRA) COO Steven Leonard Chapman sold 45,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 11th. The stock was sold at an average price of $25.16, for a total transaction of $1,132,200.00. Following the sale, the chief operating officer now directly owns 16,628 shares of the company’s stock, valued at approximately $418,360.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Steven Leonard Chapman also recently made the following trade(s):

  • On Monday, June 25th, Steven Leonard Chapman sold 86,919 shares of Natera stock. The stock was sold at an average price of $18.00, for a total transaction of $1,564,542.00.

Shares of Natera stock traded down $2.02 during midday trading on Friday, reaching $23.37. The company had a trading volume of 42,706 shares, compared to its average volume of 659,987. The company has a debt-to-equity ratio of -3.32, a current ratio of 1.69 and a quick ratio of 1.56. The firm has a market cap of $1.52 billion, a P/E ratio of -10.36 and a beta of 2.21. Natera Inc has a 1-year low of $8.60 and a 1-year high of $29.62.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Wednesday, August 8th. The medical research company reported ($0.55) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.55). The business had revenue of $63.07 million during the quarter, compared to analyst estimates of $61.71 million. Natera had a negative net margin of 59.07% and a negative return on equity of 752.93%. Natera’s revenue for the quarter was up 20.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.55) earnings per share. sell-side analysts expect that Natera Inc will post -2.05 EPS for the current year.

Institutional investors have recently modified their holdings of the stock. Tygh Capital Management Inc. increased its holdings in shares of Natera by 32.3% in the second quarter. Tygh Capital Management Inc. now owns 300,036 shares of the medical research company’s stock valued at $5,647,000 after purchasing an additional 73,301 shares in the last quarter. Sofinnova Ventures Inc acquired a new stake in shares of Natera in the first quarter valued at approximately $28,742,000. Trexquant Investment LP acquired a new stake in shares of Natera in the first quarter valued at approximately $119,000. EAM Investors LLC acquired a new stake in shares of Natera in the second quarter valued at approximately $3,868,000. Finally, Prescott Group Capital Management L.L.C. acquired a new stake in shares of Natera in the second quarter valued at approximately $572,000. 66.31% of the stock is owned by institutional investors and hedge funds.

Several analysts have recently weighed in on the stock. Piper Jaffray Companies raised their price objective on shares of Natera to $27.00 and gave the stock an “overweight” rating in a report on Thursday, August 9th. BidaskClub lowered shares of Natera from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 30th. Zacks Investment Research raised shares of Natera from a “sell” rating to a “hold” rating in a report on Wednesday, July 11th. Craig Hallum set a $23.00 price objective on shares of Natera and gave the stock a “positive” rating in a report on Thursday, June 28th. Finally, TheStreet raised shares of Natera from a “d” rating to a “c-” rating in a report on Thursday, August 9th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $23.14.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

See Also: How to Calculate Compound Annual Growth Rate (CAGR)

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.